Onyx Bio, a startup developing a virtual immune system to accelerate the development of precision medicines, has secured $8.0M in seed funding. The company's approach centers on generating rich, longitudinal multiomics data, anchored in clinical context, to deeply profile the progression of autoimmune diseases.
Believing that high-quality biological data is the cornerstone of scientific advancement, Onyx Bio applies advanced AI to its growing biorespository and datasets. This allows it to gain unprecedented insight into immune function, aiming to illuminate new frontiers in treatment and prevention for conditions that once seemed intractable.
